Nuveen LLC acquired a new stake in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 33,193 shares of the company's stock, valued at approximately $895,000. Nuveen LLC owned approximately 0.18% of USANA Health Sciences at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in USNA. Dimensional Fund Advisors LP increased its position in USANA Health Sciences by 7.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company's stock valued at $27,751,000 after acquiring an additional 55,059 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in USANA Health Sciences by 23.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 173,997 shares of the company's stock valued at $4,693,000 after acquiring an additional 33,141 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of USANA Health Sciences during the 1st quarter worth approximately $888,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of USANA Health Sciences during the 1st quarter worth approximately $870,000. Finally, Jane Street Group LLC grew its position in shares of USANA Health Sciences by 330.0% during the 4th quarter. Jane Street Group LLC now owns 39,979 shares of the company's stock worth $1,435,000 after buying an additional 30,681 shares during the period. Institutional investors and hedge funds own 54.25% of the company's stock.
Insider Activity at USANA Health Sciences
In other USANA Health Sciences news, Director Gilbert A. Fuller sold 1,058 shares of the company's stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $29.10, for a total value of $30,787.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Mulham Mulham sold 3,515 shares of the company's stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the completion of the sale, the insider directly owned 9,260 shares of the company's stock, valued at $280,207.60. The trade was a 27.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,073 shares of company stock valued at $151,982 in the last ninety days. Insiders own 0.63% of the company's stock.
USANA Health Sciences Stock Up 0.0%
NYSE USNA traded up $0.01 during trading on Friday, reaching $31.78. 234,152 shares of the stock traded hands, compared to its average volume of 90,734. USANA Health Sciences, Inc. has a fifty-two week low of $23.10 and a fifty-two week high of $41.83. The firm has a market cap of $580.65 million, a price-to-earnings ratio of 17.65, a price-to-earnings-growth ratio of 1.01 and a beta of 0.64. The stock's 50-day moving average price is $31.24 and its 200 day moving average price is $29.58.
USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.54 by $0.20. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. The firm had revenue of $235.85 million during the quarter, compared to the consensus estimate of $225.20 million. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. Analysts anticipate that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Two equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $36.00.
Get Our Latest Stock Report on USANA Health Sciences
About USANA Health Sciences
(
Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
See Also
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
